No Data
Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.
"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
AIRDOC-B: SUPPLEMENTAL ANNOUNCEMENT IN RELATIONTO THE ANNUAL REPORT OF THE COMPANYFOR THE YEAR ENDED DECEMBER 31, 2023
AIRDOC-B: 2024 INTERIM REPORT
Eagle Eye Technology (02251.HK): The gradual release of growth elasticity, looking at AI diagnosis and treatment integrated commercial application models.
In recent years, AI technology has triggered an unprecedented revolution in the medical field, from assisting in diagnosis to empowering medical imaging, and even to drug development. The power of AI is gradually permeating and reshaping every corner of the medical industry. In this context, how can investors seize the deterministic opportunities in the AI medical field? Which companies can stand out and become the backbone of the industry? In the eyes of industry observers, AI medical companies that are the first to explore commercial landing paths and have self-regenerating capabilities are more investment-worthy. These companies generally have strong research and development capabilities and market insights, allowing them to stand firm in intense market competition.
Eagle Eye Technology-B (02251.HK): Volatility in the out-of-hospital market in the first half of 2024, continuous layout of grassroots business.
1H24 performance lower than our expectations Company announced 1H24 performance: revenue of 93.71 million yuan (+13.6% YoY), a net loss attributable to shareholders of 80.5 million yuan, a 98.7% year-on-year increase in losses, lower than our expectations, mainly
No Data
No Data